Our top pick for
Xenetic Biosciences, Inc is a biotechnology business based in the US. Xenetic Biosciences shares (XBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Xenetic Biosciences employs 4 staff and has a trailing 12-month revenue of around USD$302,676.
|Latest market close||USD$3.17|
|52-week range||USD$0.44 - USD$1.7698|
|50-day moving average||USD$0.8828|
|200-day moving average||USD$1.0097|
|Wall St. target price||USD$2.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-12.323|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||N/A|
|1 month (2020-12-15)||N/A|
|3 months (2020-10-15)||N/A|
|6 months (2020-07-15)||N/A|
|1 year (2020-01-15)||N/A|
|2 years (2019-01-15)||N/A|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
Valuing Xenetic Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xenetic Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Xenetic Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Xenetic Biosciences shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$17,066|
|Return on assets TTM||-18.65%|
|Return on equity TTM||-83.03%|
|Market capitalisation||USD$7.4 million|
TTM: trailing 12 months
There are currently 578,104 Xenetic Biosciences shares held short by investors – that's known as Xenetic Biosciences's "short interest". This figure is 1.6% down from 587,535 last month.
There are a few different ways that this level of interest in shorting Xenetic Biosciences shares can be evaluated.
Xenetic Biosciences's "short interest ratio" (SIR) is the quantity of Xenetic Biosciences shares currently shorted divided by the average quantity of Xenetic Biosciences shares traded daily (recently around 275287.61904762). Xenetic Biosciences's SIR currently stands at 2.1. In other words for every 100,000 Xenetic Biosciences shares traded daily on the market, roughly 2100 shares are currently held short.
However Xenetic Biosciences's short interest can also be evaluated against the total number of Xenetic Biosciences shares, or, against the total number of tradable Xenetic Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xenetic Biosciences's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Xenetic Biosciences shares in existence, roughly 90 shares are currently held short) or 0.1038% of the tradable shares (for every 100,000 tradable Xenetic Biosciences shares, roughly 104 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xenetic Biosciences.
Find out more about how you can short Xenetic Biosciences stock.
We're not expecting Xenetic Biosciences to pay a dividend over the next 12 months.
Xenetic Biosciences's shares were split on a 1:12 basis on 25 June 2019. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xenetic Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Xenetic Biosciences shares which in turn could have impacted Xenetic Biosciences's share price.
Over the last 12 months, Xenetic Biosciences's shares have ranged in value from as little as $0.44 up to $1.7698. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenetic Biosciences's is 2.4025. This would suggest that Xenetic Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.